Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Solventum Corporation Stock Underperforming the Dow?

Minnesota-based Solventum Corporation (SOLV) officially spun off from 3M to become an independent healthcare company in 2024. The company is a global healthcare innovator that blends material science, data intelligence, and digital technology to solve some of healthcare’s most pressing challenges. 

Through its MedSurg, Dental Solutions, and Health Information Systems segments, the company delivers a diverse portfolio designed to enhance patient outcomes, streamline clinical workflows, and modernize care delivery. Large-cap status begins at $10 billion, and Solventum Corporation is already there. With a market capitalization of around $11.4 billion, the company firmly holds its ground in large-cap territory. 

Fundamentals

See More
  • Market Capitalization, $K 44,485,240
  • Shares Outstanding, K 284,742
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,675 M
  • EBITDA $ 5,137 M
  • 60-Month Beta 0.24
  • Price/Sales 2.01
  • Price/Cash Flow 6.78
  • Price/Book 1.76

Options Overview Details

View History
  • Implied Volatility 30.92% (-0.20%)
  • Historical Volatility 29.32%
  • IV Percentile 71%
  • IV Rank 57.48%
  • IV High 40.49% on 04/10/25
  • IV Low 17.97% on 08/15/25
  • Expected Move (DTE 24) 8.16 (5.22%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 475
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 10,235
  • Open Int (30-Day) 15,874
  • Expected Range 148.07 to 164.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.77
  • Number of Estimates 6
  • High Estimate 2.78
  • Low Estimate 2.76
  • Prior Year 3.35
  • Growth Rate Est. (year over year) -17.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.74 +1.62%
on 03/20/26
187.35 -16.61%
on 02/24/26
-28.11 (-15.25%)
since 02/23/26
3-Month
151.32 +3.24%
on 01/02/26
187.35 -16.61%
on 02/24/26
+2.40 (+1.56%)
since 12/23/25
52-Week
127.59 +22.45%
on 11/06/25
187.35 -16.61%
on 02/24/26
-24.77 (-13.68%)
since 03/21/25

Most Recent Stories

More News
Is Solventum Corporation Stock Underperforming the Dow?

While Solventum has lagged behind the broader Dow Jones Industrial Average, analysts remain optimistic about the stock.

SOLV : 65.69 (-0.14%)
BDX : 156.23 (+1.36%)
$DOWI : 46,208.47 (+1.38%)
How Is Baxter's Stock Performance Compared to Other Medical Devices Stocks?

Baxter has notably underperformed the Medical Devices industry over the past year, and analysts are cautious about the stock’s prospects.

BDX : 156.23 (+1.36%)
BAX : 16.61 (+2.85%)
IHI : 54.50 (+0.11%)
3 Reasons BDX is Risky and 1 Stock to Buy Instead

3 Reasons BDX is Risky and 1 Stock to Buy Instead

BDX : 156.23 (+1.36%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

COLL : 34.74 (-1.99%)
JAZZ : 182.32 (+0.94%)
BDX : 156.23 (+1.36%)
BD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor™ 1000mL for Wound Irrigation

The first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating...

BDX : 156.23 (+1.36%)
Is Becton, Dickinson and Company Stock Outperforming the Dow?

As Becton, Dickinson and Company has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

BDX : 156.23 (+1.36%)
$DOWI : 46,208.47 (+1.38%)
ISRG : 478.04 (+0.01%)
How Is Stryker's Stock Performance Compared to Other Healthcare Stocks?

Despite Stryker’s underperformance relative to its peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

XLV : 144.77 (-0.39%)
SYK : 332.59 (-0.92%)
BDX : 156.23 (+1.36%)
Becton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase

FRANKLIN LAKES, N.J. , Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the " Company " or " BD "), a leading global medical technology company, today announced...

BDX : 156.23 (+1.36%)
Is Intuitive Surgical Stock Underperforming the Dow?

While Intuitive Surgical has underperformed the Dow over the past year, analysts remain moderately bullish on its future outlook.

BDX : 156.23 (+1.36%)
$DOWI : 46,208.47 (+1.38%)
ISRG : 478.04 (+0.01%)
Becton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap and Aggregate Offer Cap

FRANKLIN LAKES, N.J. , Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the " Company " or " BD "), a leading global medical technology company, today announced...

BDX : 156.23 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 160.44
2nd Resistance Point 159.27
1st Resistance Point 157.75
Last Price 156.23
1st Support Level 155.06
2nd Support Level 153.89
3rd Support Level 152.37

See More

52-Week High 187.35
Fibonacci 61.8% 164.52
Fibonacci 50% 157.47
Last Price 156.23
Fibonacci 38.2% 150.42
52-Week Low 127.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.